5-Amino-1MQ (50 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Dosing is a single morning dose only, taken orally as the primary route, with subcutaneous injection as the alternative. Splitting the dose across the day, or taking it in the afternoon or evening, causes insomnia in most users; that is the mechanism working, meaning elevated cellular energy from increased NAD+ and mitochondrial activity, rather than an adverse effect, and the fix is timing rather than dose reduction. The oral route favors the chloride salt form, which carries most of the potency difference between batches. Injectable protocols are less common and less well documented than oral: the subcutaneous route is supported by user reports but has no published clinical PK data at these doses, the same morning only timing applies, and mild stinging may occur from the quinolinium structure. Subcutaneous sites are rotated systematically across abdomen, thighs, and upper arms.

Results Timeline

Sequence described in the research record. Individual response varies.

• Weeks 1 to 2: energy and endurance improvements appear first, ahead of any visible change in composition.
• Weeks 1 to 2 (oral): the tolerance phase holds at 50 mg per day as a single morning dose.
• Weeks 3 to 6 (oral): the active phase runs 100 to 150 mg per day, still as a single morning dose.
• Weeks 4 to 6: body composition changes become visible in responders, downstream of mitochondrial upregulation.
• Weeks 7 and beyond: an 8 to 12 week off-cycle follows, reflecting the absence of long-term safety data.

Reconstitution Steps

1. Remove the vial from freezer storage and allow it to equilibrate at room temperature for 15 to 20 minutes.
2. Draw 2.5 mL bacteriostatic water with a sterile syringe.
3. Inject slowly down the vial wall; avoid foaming.
4. Gently swirl until dissolved (solution should be clear; do not shake).
5. Label with date and concentration; refrigerate at 2 to 8 °C, protected from light, and use within 2 to 4 weeks. At 20 mg/mL, 1 unit = 0.01 mL » 0.2 mg (200 mcg) on a U-100 insulin syringe, so 500 mcg = 2.5 units, 1 mg = 5 units, 2.5 mg = 12.5 units, and 3.3 mg = 16.5 units.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized vial: store at minus 20 °C in dry, dark conditions; stable up to 24 months.
• Reconstituted: refrigerate at 2 to 8 °C and use within 2 to 4 weeks; do not refreeze reconstituted solution.

• Oral capsules: room temperature, dry, and dark.
• Allow vials to reach room temperature before reconstitution to prevent condensation.

Supplies Needed

The figures below are based on a 4 to 6 week cycle with a morning dose only, at 100 mg per day orally, which is 700 mg per week, or 1 to 2.5 mg per day on the subcutaneous alternative.

Peptide Vials (5-Amino-1MQ, 50 mg vial):

• Oral at 100 mg per day for 4 weeks totals 2,800 mg, planned as about 1 bottle of 50 mg capsules (typical 30 count), with about 2 bottles for a 6 week cycle at 150 mg per day. On the subcutaneous alternative, 4 weeks at 1 mg per day totals 28 mg, about 1 vial of 50 mg, and 4 weeks at 2.5 mg per day totals 70 mg, about 2 vials.

Insulin Syringes (U-100):

• Per week (once daily, subcutaneous only): 7 U-100 insulin syringes.
• Full cycle: 28 syringes over 4 weeks and 42 over 6 weeks; the oral route needs none.

Bacteriostatic Water (10 mL bottles):

• Each 50 mg vial takes 2.5 mL, so one 10 mL bottle covers 4 vials, which is more than enough for the 1 to 2 vials used over a 4 to 6 week subcutaneous cycle.

Alcohol Swabs:

• Per injection: 2 swabs, one for the vial stopper and one for the site, which is 14 per week.
• Full cycle: 56 swabs over 4 weeks and 84 over 6 weeks; one 100 count box covers either.

Important Notes

Practical considerations for consistency and safety.

• Salt form matters on the oral route. The chloride salt (HCl, MW about 212.67 g/mol) delivers about 83% active compound per mg, while the iodide salt (HI, MW about 304.13 g/mol) delivers only about 58%. A 150 mg iodide dose provides about 87 mg active versus about 125 mg from chloride, a 44% potency gap, and this single variable explains many reports of no effect. Sourcing should be confirmed as the chloride form.
• Morning dose only. Late dosing causes insomnia; if insomnia appears the timing shifts earlier rather than the dose coming down.
• Cycle 4 to 6 weeks on and 8 to 12 weeks off. NNMT is expressed in liver as well as adipose tissue, and conservative cycling reflects the absence of long-term safety data.
• Common side effects are headaches in the first week (most frequent, usually resolving), irritability at higher doses, and insomnia if dosed too late. Persistent headaches past week 1 call for a dose reduction. Energy precedes composition: subjective energy and endurance appear in weeks 1 to 2, while fat loss is downstream of mitochondrial upregulation at weeks 4 to 6.
• Responder profile: leaner individuals (sub-15% body fat), an optimized training and nutrition baseline, and the chloride salt form. Higher body fat percentage and the iodide salt form correlate with non-response in community reports. Stacking partners include NMN or NR (complementary, since 5-Amino-1MQ plugs the drain while precursors add supply), MOTS-c for AMPK and NAD+ preservation in the Mito Stack, GLP-1 agonists for appetite plus adipocyte expenditure in the Recomposition Stack, and injectable L-carnitine for fatty acid transport.
• Regulatory Note: 5-Amino-1MQ is not an approved drug and is supplied for research use only, not for human consumption. There is no human safety data; it is avoided in pregnancy, breastfeeding, active cancer, and significant hepatic impairment, and all evidence remains preclinical.

How This Works

NNMT is a cytosolic enzyme that methylates nicotinamide using S-adenosylmethionine (SAM) as the methyl donor. The product, 1-methylnicotinamide, cannot enter NAD+ salvage, so NNMT activity creates a dual drain: nicotinamide is lost from the NAD+ pool and SAM is consumed away from other methylation reactions. In obesity, NNMT is significantly overexpressed in white adipose tissue, scaling with visceral fat burden, and the downstream consequence is that adipocyte NAD+ falls, sirtuin activity drops, mitochondrial biogenesis stalls, and the fat cell shifts toward storage. 5-Amino-1MQ inhibits NNMT directly, so preserved nicotinamide re-enters the salvage pathway through NAMPT and raises adipocyte NAD+. Restored NAD+ activates SIRT1, enhances AMPK signaling, increases mitochondrial density, and shifts the adipocyte toward energy expenditure. This is mechanistically distinct from precursor loading with NMN or NR: rather than adding more substrate, 5-Amino-1MQ stops the loss of substrate that already exists, which makes the two approaches complementary. In Kraus 2014 (Nature), NNMT knockdown in white adipose tissue protected mice from diet-induced obesity without affecting food intake or lean mass, and in Neelakantan 2018, 5-Amino-1MQ reduced body weight and fat mass in DIO mice via increased adipocyte energy expenditure.

Benefits & Side Effects

Observations from the published record.

• Energy and endurance: the most consistent positive signal in user communities, appearing within 1 to 2 weeks and reflecting upstream mitochondrial biogenesis before downstream fat oxidation.
• Body composition (preclinical): reduced body weight and fat mass in DIO mice without affecting food intake or lean mass (Neelakantan 2018).
• NAD+ elevation and sirtuin signaling: elevated intracellular NAD+ specifically in adipocytes through preserved salvage pathway flux, with enhanced SIRT1 activity, mitochondrial density, and fatty acid oxidation in preclinical models.
• Hepatic NNMT context: Hong 2015 demonstrated that NNMT regulates hepatic nutrient handling through Sirt1 stabilization, which is relevant to the cycling rationale.
• Side effects: headaches (most common, week 1), insomnia (a timing issue rather than a dose issue), irritability at higher doses, and mild subcutaneous injection-site stinging from the quinolinium structure.
• Polarized response pattern and safety: about 40% report clear benefits, about 40% report nothing, and about 20% report significant results, with salt form, body fat percentage, and protocol context driving much of the variance. No human clinical trials have been published, all efficacy data is preclinical, and long-term safety is unknown.

Lifestyle Factors

Complementary strategies for best outcomes.

• Optimized baseline matters. 5-Amino-1MQ targets the NNMT bottleneck that becomes relevant when training, nutrition, and body fat are already in a reasonable range; it is not a fix for a poor baseline. A protein-forward diet tailored to energy needs supports adipocyte signaling and lean mass preservation during fat loss.
• Combine resistance and aerobic training; preclinical evidence on grip strength in aged mice suggests synergy with exercise.
• Sleep hygiene of 7 to 9 hours protects the circadian NAD+ rhythm, and morning dosing protects sleep.
• Stress management and limited alcohol: chronic stress drains NAD+ through PARP overactivation, and ethanol metabolism consumes NAD+ acutely, both working against the protocol's mechanism.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Kraus D et al. NNMT knockdown protects against diet-induced obesity (Nature, 2014).
2. Neelakantan H et al. Selective NNMT inhibitors reverse high-fat diet-induced obesity in mice (Biochem Pharmacol, 2018).
3. Neelakantan H et al. Structure-activity relationship for small molecule NNMT inhibitors (J Med Chem, 2017).
4. Hong S et al. NNMT regulates hepatic nutrient metabolism through Sirt1 stabilization (Sci Rep, 2015).
5. Ulanovskaya OA et al. NNMT promotes epigenetic remodeling via methylation sink mechanism (Nat Chem Biol, 2013).
6. Pissios P. Nicotinamide N-methyltransferase: more than a vitamin B3 clearance enzyme (Trends Pharmacol Sci, 2020).